An In-vivo 1H-MRS short-echo time technique at 7T: Quantification of metabolites in chronic multiple sclerosis and neuromyelitis optica brain lesions and normal appearing brain tissue

An In-vivo 1H-MRS short-echo time technique at 7T: Quantification of metabolites in chronic multiple sclerosis and neuromyelitis optica brain lesions and normal appearing brain tissue

Magnetic Resonance Spectroscopy (MRS) allows for the non-invasive quantification of neurochemicals and has the potential to differentiate between the pathologically distinct diseases, multiple sclerosis (MS) and AQP4Ab-positive neuromyelitis optica spectrum disorder (AQP4Ab-NMOSD). In this study we...

Bibliografske podrobnosti
Main Authors:	Tackley, G, Kong, Y, Minne, R, Messina, S, Winkler, A, Cavey, A, Everett, R, DeLuca, GC, Weir, A, Craner, M, Tracey, I, Palace, J, Stagg, CJ, Emir, U
Format:	Journal article
Jezik:	English
Izdano:	Elsevier 2021

Podobne knjige/članki

An In-vivo 1H-MRS short-echo time technique at 7T: Quantification of metabolites in chronic multiple sclerosis and neuromyelitis optica brain lesions and normal appearing brain tissue
od: George Tackley, et al.
Izdano: (2021-09-01)

Magnetic resonance imaging in neuromyelitis optica.
od: Tackley, G, et al.
Izdano: (2014)

The in-vivo study of pain in neuromyelitis optica
od: Tackley, G
Izdano: (2017)

The evolving clinical spectrum of neuromyelitis optica
od: Viegas, S, et al.
Izdano: (2008)

Paediatric neuromyelitis optica: clinical, MRI of the brain and prognostic features.
od: Absoud, M, et al.
Izdano: (2014)

The borderland of neuromyelitis optica.
od: Matthews, L, et al.
Izdano: (2009)

Clinical and brain MRI appearances in neuromyelitis optica
od: Shijuan ZHANG, et al.
Izdano: (2011-06-01)

Symptomatic, radiological and pathological involvement of the hypothalamus in neuromyelitis optica.
od: Viegas, S, et al.
Izdano: (2009)

Symptomatic brain involvement as the initial manifestation of neuromyelitis optica.
od: Min, J, et al.
Izdano: (2013)

Use of mitoxantrone in neuromyelitis optica.
od: Kitley, J, et al.
Izdano: (2011)

Neuromyelitis optica relapses: race and rate, immunosuppression and impairment
od: Tackley, G, et al.
Izdano: (2016)

TREATMENT OF NEUROMYELITIS OPTICA WITH AZATHIOPRINE
od: Elsone, L, et al.
Izdano: (2012)

A practical guide to the treatment of neuromyelitis optica.
od: Palace, J, et al.
Izdano: (2012)

Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset.
od: Collongues, N, et al.
Izdano: (2013)

NEUROMYELITIS OPTICA SPECTRUM AND RELATIONSHIP WITH AQUAPORIN-4 ANTIBODY DISEASE: THE OXFORD COHORT
od: Leite, M, et al.
Izdano: (2009)

Antibodies to aquaporin-1 are not present in neuromyelitis optica
od: Waters, P, et al.
Izdano: (2015)

The role of imaging in diagnosing neuromyelitis optica spectrum disorder
od: Matthews, L, et al.
Izdano: (2014)

Neuroimmunology: towards more-accurate diagnosis in neuromyelitis optica.
od: Fujihara, K, et al.
Izdano: (2014)

The role of imaging in diagnosing neuromyelitis optica spectrum disorder
od: Matthews, L, et al.
Izdano: (2013)

Neuromyelitis Optica
od: Goyal V, et al.
Izdano: (2009-10-01)

Neuromyelitis optica
od: Jacob Anu, et al.
Izdano: (2007-01-01)

NMO-IgG in the diagnosis of neuromyelitis optica.
od: Jarius, S, et al.
Izdano: (2007)

Treatment of Neuromyelitis Optica: Review and Recommendations.
od: Kimbrough, D, et al.
Izdano: (2012)

Neuromyelitis optica spectrum disorder and multiple sclerosis can be distinguished on the basis of MRI brain lesion characteristics
od: Matthews, L, et al.
Izdano: (2012)

Running a mitoxantrone service for multiple sclerosis
od: Craner, M, et al.
Izdano: (2006)

Seasonal pattern of variation in neuromyelitis optica relapses
od: Elsone, L, et al.
Izdano: (2012)

A mathematical model of cellular swelling in Neuromyelitis optica
od: Laranjeira, S, et al.
Izdano: (2017)

Brain abnormalities in Sjogren syndrome with recurrent CNS manifestations: association with neuromyelitis optica.
od: Min, J, et al.
Izdano: (2009)

Differential diagnosis of neuromyelitis optica spectrum disorders
od: Sung-Min Kim, et al.
Izdano: (2017-07-01)

Treatment of neuromyelitis optica: Review and recommendations
od: Kimbrough, D, et al.
Izdano: (2012)

Pregnancy and neuromyelitis optica
od: Qiu-ying MA, et al.
Izdano: (2016-10-01)

NEUROMYELITIS OPTICA IN SOUTH WALES AND THE SOUTH WEST OF ENGLAND
od: Luppe, S, et al.
Izdano: (2012)

An audit of the diagnostic usefulness of the NMO-IgG assay for neuromyelitis optica
od: Littleton, E, et al.
Izdano: (2006)

Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica.
od: Paul, F, et al.
Izdano: (2007)

Effect of IgG from seronegative and seropositive neuromyelitis optica patients on mouse brain
od: Saadoun, S, et al.
Izdano: (2013)

Influence of pregnancy on neuromyelitis optica spectrum disorder.
od: Kim, W, et al.
Izdano: (2012)

Risk factors for immunosuppression-associated infections in aquaporin-4 antibody mediated neuromyelitis optica spectrum disorders
od: Cheng, F, et al.
Izdano: (2014)

The eyes show what the brain has: A case report on neuromyelitis optica
od: Ayushi Choudhary, et al.
Izdano: (2021-01-01)

Markedly increased IP-10 production by blood-brain barrier in neuromyelitis optica.
od: Fumitaka Shimizu, et al.
Izdano: (2015-01-01)

The influence of smoking on the pattern of disability and relapse risk in AQP4-positive Neuromyelitis Optica Spectrum Disorder, MOG-Ab Disease and Multiple Sclerosis
od: Messina, S, et al.
Izdano: (2021)